nach oben

Erschienen in:

06.04.2022 | Original Article

Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma

verfasst von: Huiyun Yang, Rongjun Zhang, Ruyun Zhang, Bin Zhang, Yuan Xie, Guanjie Qin, Yunyan Mo, Xiaolan Ruan, Dr. Wei Jiang

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Objective

To develop and validate a nomogram to predict distant metastasis-free survival of patients with locoregionally advanced nasopharyngeal carcinoma.

Methods

We collected the total clinical data of 820 nasopharyngeal carcinoma (NPC) patients, of whom 482 formed the training cohort from one hospital and 328 made up the validation cohort from another hospital. By analyzing the prognosis of all patients after intensity-modulated radiotherapy by univariate and multivariate Cox regression models, a nomogram related to DMFS was created in the training cohort. The discriminatory and calibration power of the nomogram was successively assessed in the training and validation cohorts by the C‑index and calibration curve. The predictive ability for 3‑year DMFS was compared between the nomogram and TNM stage using ROC curves. Patients were divided into different risk groups based on scores calculated from the nomogram.

Results

Age, lymph node gross tumor volume (GTVnd), and gross tumor volume of the nasopharynx (GTVnx) were the factors included in the nomogram. The C‑index of the nomogram was 0.721 in the training cohort and 0.750 in the validation cohort. The calibration curves were satisfactory. Patients in the high-risk group were more likely to develop metastases.

Conclusion

A nomogram incorporating age, GTVnd, and GTVnx showed good performance for predicting DMFS in patients with locoregionally advanced NPC.

Nur mit Berechtigung zugänglich

Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3(4):524–548. https://doi.org/10.1001/jamaoncol.2016.5688CrossRefPubMed

Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L et al (2005) Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23(28):6966–6975. https://doi.org/10.1200/jco.2004.00.7542CrossRefPubMed

Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY et al (2016) Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 17(11):1509–1520. https://doi.org/10.1016/s1470-2045(16)30410-7CrossRefPubMed

Yang Q, Cao SM, Guo L, Hua YJ, Huang PY, Zhang XL et al (2019) Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer 119:87–96. https://doi.org/10.1016/j.ejca .2019.07.007CrossRef

Jin Y, Shi YX, Cai XY, Xia XY, Cai YC, Cao Y et al (2012) Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol 138(10):1717–1725. https://doi.org/10.1007/s00432-012-1219-xCrossRefPubMed

Lee AW, Ma BB, Ng WT, Chan AT (2015) Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol 33(29):3356–3364. https://doi.org/10.1200/jco.2015.60.9347CrossRefPubMed

Edge SB, Compton CC (2010) The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474. https://doi.org/10.1245/s10434-010-0985-4CrossRefPubMed

Jiang Y, Qu S, Pan X, Huang S, Zhu X (2020) Prognostic nomogram for locoregionally advanced nasopharyngeal carcinoma. Sci Rep 10(1):861. https://doi.org/10.1038/s41598-020-57968-xCrossRefPubMedPubMedCentral

Liu LT, Chen QY, Tang LQ, Guo SS, Guo L, Mo HY et al (2019) Neoadjuvant or adjuvant chemotherapy plus concurrent CRT versus concurrent CRT alone in the treatment of nasopharyngeal carcinoma: a study based on EBV DNA. J Natl Compr Canc Netw 17(6):703–710. https://doi.org/10.6004/jnccn.2018.7270CrossRefPubMed

10.

Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T et al (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16(4):1310–1317. https://doi.org/10.1200/jco.1998.16.4.1310CrossRefPubMed

11.

Chen BB, Lu SY, Peng H, Sun FF, Zhu J, Wang J et al (2020) Comparison of long-term outcomes and sequelae between children and adult nasopharyngeal carcinoma treated with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 106(4):848–856. https://doi.org/10.1016/j.ijrobp.2019.11.035CrossRefPubMed

12.

Chen YP, Zhao BC, Chen C, Shen LJ, Gao J, Mai ZY et al (2015) Pretreatment platelet count improves the prognostic performance of the TNM staging system and aids in planning therapeutic regimens for nasopharyngeal carcinoma: a single-institutional study of 2,626 patients. Chin J Cancer 34(3):137–146. https://doi.org/10.1186/s40880-015-0006-xCrossRefPubMed

13.

Gao J, Hu JY, Xia YF, Yi W, Tao YL, Li G (2010) Continuous fall in hemoglobin level is a poor prognostic factor in patients with nasopharyngeal carcinoma treated with radiotherapy. Chin J Cancer 29(5):561–566. https://doi.org/10.5732/cjc.009.10533CrossRefPubMed

14.

Feng M, Wang W, Fan Z, Fu B, Li J, Zhang S et al (2013) Tumor volume is an independent prognostic indicator of local control in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Radiat Oncol 8:208. https://doi.org/10.1186/1748-717x-8-208CrossRefPubMedPubMedCentral

15.

Chen S, Liu Y, Yang J, Liu Q, You H, Dong Y et al (2019) Development and validation of a nomogram for predicting survival in male patients with breast cancer. Front Oncol 9:361. https://doi.org/10.3389/fonc.2019.00361CrossRefPubMedPubMedCentral

16.

Zheng H, Zhao Y, He Q, Hao H, Tian Y, Zou B et al (2020) Multi-institutional development and validation of a nomogram to predict recurrence after curative resection of gastric neuroendocrine/mixed adenoneuroendocrine carcinoma. Gastric Cancer. https://doi.org/10.1007/s10120-020-01119-8CrossRefPubMed

17.

Liang W, Zhang L, Jiang G, Wang Q, Liu L, Liu D et al (2015) Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. J Clin Oncol 33(8):861–869. https://doi.org/10.1200/jco.2014.56.6661CrossRefPubMed

18.

Sun XS, Li XY, Xiao BB, Liu SL, Chen QY, Tang LQ et al (2020) Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: A study based on a phase III randomized clinical trial with 10-year follow-up. Oral Oncol 100:104490. https://doi.org/10.1016/j.oraloncology.2019.104490CrossRefPubMed

19.

Li QJ, Mao YP, Guo R, Huang CL, Fang XL, Ma J et al (2020) A nomogram based on serum biomarkers and clinical characteristics to predict survival in patients with non-metastatic nasopharyngeal carcinoma. Front Oncol 10:594363. https://doi.org/10.3389/fonc.2020.594363CrossRefPubMedPubMedCentral

20.

Gu B, Zhang J, Ma G, Song S, Shi L, Zhang Y et al (2020) Establishment and validation of a nomogram with intratumoral heterogeneity derived from (18)F-FDG PET/CT for predicting individual conditional risk of 5‑year recurrence before initial treatment of nasopharyngeal carcinoma. BMC Cancer 20(1):37. https://doi.org/10.1186/s12885-020-6520-5CrossRefPubMedPubMedCentral

21.

Guan W, Xie K, Fan Y, Lin S, Huang R, Tang Q et al (2020) Development and validation of a nomogram for predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma. Front Oncol 10:594494. https://doi.org/10.3389/fonc.2020.594494CrossRefPubMedPubMedCentral

22.

Zhang B, Tian J, Dong D, Gu D, Dong Y, Zhang L et al (2017) Radiomics features of multiparametric MRI as novel prognostic factors in advanced nasopharyngeal carcinoma. Clin Cancer Res 23(15):4259–4269. https://doi.org/10.1158/1078-0432.Ccr-16-2910CrossRefPubMed

23.

Zhang LL, Xu F, He WT, Huang MY, Song D, Li YY et al (2020) Development and validation of a prognostic nomogram for the pre-treatment prediction of early metachronous metastasis in endemic nasopharyngeal carcinoma: a big-data intelligence platform-based analysis. Ther Adv Med Oncol 12:1758835920978132. https://doi.org/10.1177/1758835920978132CrossRefPubMedPubMedCentral

24.

Pan JJ, Ng WT, Zong JF, Lee SW, Choi HC, Chan LL et al (2016) Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer 122(21):3307–3315. https://doi.org/10.1002/cncr.30198CrossRefPubMed

25.

Huang SJ, Tang YY, Liu HM, Tan GX, Wang X, Zhang H et al (2018) Impact of age on survival of locoregional nasopharyngeal carcinoma: An analysis of the Surveillance, Epidemiology, and End Results program database, 2004–2013. Clin Otolaryngol 43(5):1209–1218. https://doi.org/10.1111/coa.13124CrossRefPubMed

26.

Gomes AP, Ilter D, Low V, Endress JE, Fernández-García J, Rosenzweig A, Schild T, Broekaert D, Ahmed A, Planque M, Elia I, Han J, Kinzig C, Mullarky E, Mutvei AP, Asara J, de Cabo R, Cantley LC, Dephoure N, Fendt SM, Blenis J (2020) Age-induced accumulation of methylmalonic acid promotes tumour progression. Nature 585(7824):283–287. https://doi.org/10.1038/s41586-020-2630-0CrossRefPubMedPubMedCentral

27.

Xiao G, Cao Y, Qiu X, Wang W, Wang Y (2013) Influence of gender and age on the survival of patients with nasopharyngeal carcinoma. BMC Cancer 13:226. https://doi.org/10.1186/1471-2407-13-226CrossRefPubMedPubMedCentral

28.

Liang SB, Teng JJ, Hu XF, Yang XL, Luo M, Fang XN et al (2017) Prognostic value of total tumor volume in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. BMC Cancer 17(1):506. https://doi.org/10.1186/s12885-017-3480-5CrossRefPubMedPubMedCentral

29.

Chen QY, Guo SY, Tang LQ, Lu TY, Chen BL, Zhong QY et al (2018) Combination of tumor volume and Epstein-Barr virus DNA improved prognostic stratification of stage II nasopharyngeal carcinoma in the intensity modulated radiotherapy era: a large-scale cohort study. Cancer Res Treat 50(3):861–871. https://doi.org/10.4143/crt.2017.237CrossRefPubMed

30.

Lu L, Li J, Zhao C, Xue W, Han F, Tao T et al (2016) Prognostic efficacy of combining tumor volume with Epstein-Barr virus DNA in patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma. Oral Oncol 60:18–24. https://doi.org/10.1016/j.oraloncology.2016.06.013CrossRefPubMed

31.

Lartigau E, Le Ridant AM, Lambin P, Weeger P, Martin L, Sigal R et al (1993) Oxygenation of head and neck tumors. Cancer 71(7):2319–2325. https://doi.org/10.1002/1097-0142(19930401)71:7<2319::aid-cncr2820710724>3.0.co;2-c. PubMed PMID: 8453553CrossRef

32.

Li JY, Huang CL, Luo WJ, Zhang Y, Tang LL, Peng H et al (2019) An integrated model of the gross tumor volume of cervical lymph nodes and pretreatment plasma Epstein-Barr virus DNA predicts survival of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data intelligence platform-based analysis. Ther Adv Med Oncol 11:1758835919877729. https://doi.org/10.1177/1758835919877729CrossRefPubMedPubMedCentral

33.

Li J, Chen S, Peng S, Liu Y, Xing S, He X, Chen H (2018) Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics. Int J Biol Sci 14(5):549–556. https://doi.org/10.7150/ijbs.24374CrossRefPubMedPubMedCentral

34.

Liu SL, Bian LJ, Liu ZX, Chen QY, Sun XS, Sun R, Luo DH, Li XY, Xiao BB, Yan JJ, Lu ZJ, Yan SM, Yuan L, Tang LQ, Li JM, Mai HQ (2020) Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma. J Immunother Cancer 8(1):e205. https://doi.org/10.1136/jitc-2019-000205CrossRefPubMedPubMedCentral

35.

Bruce JP, Liu FF (2014) MicroRNAs in nasopharyngeal carcinoma. Chin J Cancer 33(11):539–544. https://doi.org/10.5732/cjc.014.10175CrossRefPubMedPubMedCentral

36.

Zhang W, Wang L, Zheng F, Zou R, Xie C, Guo Q, Hu Q, Chen J, Yang X, Yao H, Song E, Xiang Y (2015) Long noncoding RNA expression signatures of metastatic nasopharyngeal carcinoma and their prognostic value. Biomed Res Int. https://doi.org/10.1155/2015/618924CrossRefPubMedPubMedCentral

37.

Peng H, Dong D, Fang MJ, Li L, Tang LL, Chen L, Li WF, Mao YP, Fan W, Liu LZ, Tian L, Lin AH, Sun Y, Tian J, Ma J (2019) Prognostic value of deep learning PET/CT-based radiomics: potential role for future individual induction chemotherapy in advanced nasopharyngeal carcinoma. Clin Cancer Res 25(14):4271–4279. https://doi.org/10.1158/1078-0432.CCR-18-3065CrossRefPubMed

38.

Katano A, Takahashi W, Yamashita H, Yamamoto K, Ando M, Yoshida M et al (2018) Radiotherapy alone and with concurrent chemotherapy for nasopharyngeal carcinoma: a retrospective study. Medicine 97(18):e502. https://doi.org/10.1097/md.0000000000010502CrossRefPubMedPubMedCentral

39.

Peng H, Tang LL, Liu X, Chen L, Li WF, Mao YP et al (2018) Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis. BMC Cancer 18(1):323. https://doi.org/10.1186/s12885-018-4268-yCrossRefPubMedPubMedCentral

40.

You R, Hua YJ, Liu YP, Yang Q, Zhang YN, Li JB et al (2017) Concurrent chemoradiotherapy with or without anti-EGFR-targeted treatment for stage II-IVb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up. Theranostics 7(8):2314–2324. https://doi.org/10.7150/thno.19710CrossRefPubMedPubMedCentral

41.

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD (2018) NCCN guidelines insights: head and neck cancers, version 1.2018. J Natl Compr Canc Netw 16(5):479–490. https://doi.org/10.6004/jnccn.2018.0026CrossRefPubMed

Titel: Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma
verfasst von: Huiyun Yang
Rongjun Zhang
Ruyun Zhang
Bin Zhang
Yuan Xie
Guanjie Qin
Yunyan Mo
Xiaolan Ruan
Dr. Wei Jiang
Publikationsdatum: 06.04.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 9/2022
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-022-01926-1

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma

Abstract

Objective

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2022

Krebsprädispositions-Screening-Tools zur Vorhersage späterer maligner Erkrankungen bei Überlebenden nach einer Tumorerkrankung im Kindesalter

Mutagen sensitivity and risk of second cancer in younger adults with head and neck squamous cell cancer: 15-year results

Digital transfer in radiation oncology education for medical students—single-center data and systemic review of the literature

Das Rezidivmuster nach perkutaner Strahlentherapie mit und ohne zusätzliche fokale Dosiseskalation innerhalb der randomisierten FLAME-Studie für das lokale Prostatakarzinom

The value of metabolic parameters and textural analysis in predicting prognosis in locally advanced cervical cancer treated with chemoradiotherapy

Evaluating dosimetric parameters predictive of hematologic toxicity in cervical cancer patients undergoing definitive pelvic chemoradiotherapy

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie